Advertisement
Canada markets closed

  • S&P/TSX

    21,947.41
    +124.19 (+0.57%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • DOW

    38,675.68
    +450.02 (+1.18%)
     

  • CAD/USD

    0.7308
    -0.0006 (-0.08%)
     

  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     

  • Bitcoin CAD

    87,099.48
    +1,134.10 (+1.32%)
     

  • CMC Crypto 200

    1,329.30
    +52.32 (+4.10%)
     

  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     

  • RUSSELL 2000

    2,035.72
    +19.61 (+0.97%)
     

  • 10-Yr Bond

    4.5000
    -0.0710 (-1.55%)
     

  • NASDAQ

    16,156.33
    +315.37 (+1.99%)
     

  • VOLATILITY

    13.49
    -1.19 (-8.11%)
     

  • FTSE

    8,213.49
    +41.34 (+0.51%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • CAD/EUR

    0.6787
    -0.0030 (-0.44%)
     

Sanofi confirms its will supply over 125 millions Pfizer-BioNTech doses to the EU

Reuters
·1 min read

PARIS, Jan 27 (Reuters) - French pharmaceutical giant Sanofi said on Wednesday it had struck an agreement with Germany's BioNTech to supply the European Union with the company's vaccine developed in partnership with U.S. group Pfizer.

In a press release, Sanofi, which announced last month it had to delay the launch of its own vaccine jointly developed with Britain's GlaxoSmithKline, confirmed CEO Paul Hudson's comments to newspaper Le Figaro Wednesday. .

"Sanofi will provide BioNTech access to its established infrastructure and expertise to produce over 125 million doses of COVID-19 vaccine in Europe", Sanofi said in statement.

"Initial supplies will originate from Sanofi's production facilities in Frankfurt from summer of 2021", it added, saying its "priority was to continue to develop its two COVID-19 vaccine candidates". (Reporting by Sudip Kar-Gupta; Writing by Benoit Van Overstraeten; Editing by Shri Navaratnam)